We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Siemens Healthineers - Laboratory Diagnostics

Download Mobile App

New Test Detects Hard-to-Find Cervical Cancers

By LabMedica International staff writers
Posted on 08 Sep 2023
Print article
Image: The new test detects a type of cervical cancer that Pap tests often miss (Photo courtesy of MECC)
Image: The new test detects a type of cervical cancer that Pap tests often miss (Photo courtesy of MECC)

Cervical cancer is the fourth most common cancer in women, especially in lower- and middle-income countries. A particular type of cervical cancer called cervical adenocarcinoma (ADC), which often goes undetected by Pap tests, accounts for up to a quarter of all cervical cancer cases. The Pap test, a method where pathologists examine tissue samples for abnormal cells, has successfully reduced the occurrence of cervical squamous cell cancer over the past sixty years. However, ADC remains a challenge to detect with this method, leading to higher mortality rates compared to the more common squamous cell cancer.

More recently, human papillomavirus (HPV) testing has become a standard cervical cancer screening tool alongside the Pap test. HPV is responsible for nearly all cases of cervical cancer. While there are over 100 types of HPV, three particular types—HPV 16, 18, and 45—account for more than 70% of all cervical cancer cases, with over 90% of ADC cases linked to them. Current HPV tests cover these three types, helping identify women at high risk of cervical cancer. Despite the effectiveness of vaccines like Gardasil-9, which protects against nine HPV types, many older women are ineligible for vaccination. Consequently, screening and treatment remain vital for cervical cancer prevention for generations to come.

Scientists at Montefiore Einstein Cancer Center (MECC, New York, NY, USA) have developed an innovative test for detecting ADC and its precursor lesions known as adenocarcinoma in situ (AIS), which often progress to ADC. This MECC-designed HPV test evaluates HPV 16, 18, and 45 using a unique approach focused on methylation levels. Methylation, the addition of methyl (CH3) groups to specific DNA regions, is a common process in DNA, both viral and human, and plays a crucial role in altering gene expression. To develop this test, the researchers examined methylation levels in cervical tissue samples from 1,400 women who had undergone cervical cancer screening before 2014, with known cervical cancer status. They analyzed the HPVs present in the cytological samples, calculating methylation percentages for 35 different viral-genome sites. Each sample received a final "methylation score" based on the average methylation percentage across these 35 sites. They found that women with methylation scores in the top 25% had a significantly higher likelihood of developing either ADC or AIS.

"The advent of next-generation genetic testing has opened up opportunities for us to more accurately detect oncogenic HPV strains and patterns in the genomes that correspond with the development of AIS and ADC," said Robert D. Burk, M.D., who co-led the study. "Our findings, if confirmed by clinical trials, suggest that women with a high methylation score may benefit from colposcopy and specialized tissue evaluation, beyond just a Pap test, which could lead to early diagnosis and treatment for ADC or the removal of AIS lesions before they develop into ADC."

Related Links:

Platinum Supplier
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Gold Supplier
Automatic Western Blot Analyzer
Tenfly Phoenix Blot Analyzer
Blood Mixer Roller
CAPPRondo Blood Mixer Roller
Self-Sampling Terminal

Print article


Clinical Chemistry

view channel
Image: The new assays are designed to run on the B•R•A•H•M•S KRYPTOR compact PLUS clinical chemistry analyzer (Photo courtesy of Thermo Fisher)

Breakthrough Immunoassays to Aid in Risk Assessment of Preeclampsia

Preeclampsia is a life-threatening blood pressure condition that can arise during pregnancy and the postpartum phase. This severe pregnancy complication is a primary cause of maternal and fetal mortality... Read more


view channel
Image: The US FDA has cleared HemoScreen point of care CBC for direct capillary sampling (Photo courtesy of PixCell Medical)

Point of Care CBC Analyzer with Direct Capillary Sampling Enhances Ease-of-Use and Testing Throughput

The world’s only 5-part differential Complete Blood Count (CBC) analyzer that is FDA-cleared, CE-marked, and TGA-approved for point-of-care use has now been granted FDA 510(k) clearance for direct capillary... Read more


view channel
Image: Immune cells present long before infection predict flu symptoms (Photo courtesy of Shutterstock.com)

Single Blood Draw to Detect Immune Cells Present Months before Flu Infection Can Predict Symptoms

For decades, if not centuries, scientists have struggled to solve the mystery of why certain individuals fall ill to infections while others remain unaffected. In an impressive development, researchers... Read more


view channel
Image: The rapid diagnostic test could pinpoint the correct antibiotic for infection treatment in under an hour (Photo courtesy of Microplate Dx)

Point-of-Care Device to Reduce Antibiotic Susceptibility Testing Time from Days to Minutes

Antimicrobial resistance (AMR) is a significant global health issue, currently leading to over 1.27 million deaths worldwide each year. By 2050, AMR could be causing up to 10 million deaths annually, surpassing... Read more


view channel
Image: The Tasso+ device has received CE Mark certification (Photo courtesy of Tasso)

Groundbreaking Blood Lancing Device Obtains Microliter Capillary Whole Blood Samples Painlessly

A convenient, virtually pain-free blood lancet that collects whole liquid blood samples has received CE Mark designation, making the patient-centric, high-volume blood collection solution available in... Read more


view channel
Image: A new electrochemical device can quickly and inexpensively identify people at greatest risk for osteoporosis (Photo courtesy of ACS Central Science, 2023)

Electrochemical Device Identifies People at Higher Risk for Osteoporosis Using Single Blood Drop

With the global increase in life expectancy, the incidence of age-related conditions like osteoporosis is increasing. Osteoporosis, affecting around 200 million individuals worldwide, has a higher incidence... Read more


view channel
Image: The global fully automatic electrolyte analyzers market is projected to reach close to USD 0.77 billion by 2032 (Photo courtesy of 123RF)

Global Fully Automatic Electrolyte Analyzers Market Driven by Surge in Demand for Point-of-Care Testing

Fully automatic electrolyte analyzers can measure the levels of electrolytes in various bodily fluids like blood and plasma. Electrolytes are ions that have an electrical charge and are essential for multiple... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.